Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Gin-Sing (London, United Kingdom). Audit of disease targeted therapies in adult patients with pulmonary arterial hypertension. 3530

Member's Comments

No comment yet.

Related content which might interest you: Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Treatment options for paediatric pulmonary arterial hypertension Source: Eur Respir Rev 2010 19: 321-330 Year: 2010 Identification of treatment goals in paediatric pulmonary arterial hypertension Source: Eur Respir J 2014; 44: 1616-1626 Year: 2014 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations Source: Eur Respir Rev 2013; 22: 515-525 Year: 2013 Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era Source: Eur Respir J, 51 (6) 1800307; 10.1183/13993003.00307-2018 Year: 2018 Screening for pulmonary vascular disease (PVD) in patients with portal hypertension by investigating pulmonary hemodynamics during exercise Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Exercise pathophysiology in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Mechanisms of exercise intolerance in cardiorespiratory disease Year: 2007 Update on current treatment options of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018 Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy? Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Optimising pharmacotherapy in patients with pulmonary arterial hypertension and comorbidities, including lung diseases and heart failure: benefits without harm? Source: International Congress 2018 – Integrated care for patients with pulmonary vascular disease, lung diseases and heart failure Year: 2018 Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011 Optimising the management of pulmonary arterial hypertension patients: emergency treatments Source: Eur Respir Rev 2010 19: 204-211 Year: 2010 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012